HER2 Support Group Forums - View Single Post

Nguyen · 12-29-2022, 09:52 PM

Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer

https://jamanetwork.com/journals/jam...rticle/2800127

Key Points

Question What is the outcome of COVID-19 vaccination in patients with hematologic and solid cancer?

Findings In this cohort study of 289 400 vaccinated patients with cancer and 1 157 600 matched noncancer controls, patients with cancer had significantly higher risk of breakthrough SARS-CoV-2 infection and COVID-19 outcomes including hospitalization and death; the risk was substantial for patients with hematologic cancer and patients with solid cancer receiving active chemotherapy. A third vaccine dose was associated with lower risk of infection and severe outcomes.

Meaning Patients receiving cancer treatment and patients with hematologic cancer, regardless of treatment status, should be prioritized for booster vaccination, preexposure prophylaxis, and, in the event of SARS-CoV-2 infection, early antiviral therapy.

12-29-2022, 09:52 PM	#7
Nguyen Senior Member Join Date: Nov 2005 Posts: 515	Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer https://jamanetwork.com/journals/jam...rticle/2800127 Key Points Question What is the outcome of COVID-19 vaccination in patients with hematologic and solid cancer? Findings In this cohort study of 289 400 vaccinated patients with cancer and 1 157 600 matched noncancer controls, patients with cancer had significantly higher risk of breakthrough SARS-CoV-2 infection and COVID-19 outcomes including hospitalization and death; the risk was substantial for patients with hematologic cancer and patients with solid cancer receiving active chemotherapy. A third vaccine dose was associated with lower risk of infection and severe outcomes. Meaning Patients receiving cancer treatment and patients with hematologic cancer, regardless of treatment status, should be prioritized for booster vaccination, preexposure prophylaxis, and, in the event of SARS-CoV-2 infection, early antiviral therapy.